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Abstract
Summary To develop consensus on improving the management
of patients, we convened an international workshop involving
patients, clinicians, and researchers. Key findings included the
diagnostic delay and variability in subsequent management with
agreement to develop an international natural history study. We
now invite other stakeholders to join the partnership.
Purpose The aim of this study was develop a consensus on
how to improve the management of patients with fibrous dys-
plasia and prioritize areas for research
Methods An international workshop was held over 3 days
involving patients, clinicians, and researchers. Each day had
a combination of formal presentations and facilitated discus-
sions that focused on clinical pathways and research.
Results The patient workshop day highlighted the variability
of patients’ experience in getting a diagnosis, the knowledge
of general clinical staff, and understanding long-term out-
comes. The research workshop prioritized collaborations that
improved understanding of the contemporary natural history
of fibrous dysplasia/McCune-Albright syndrome (FD/MAS).
The clinical workshop outlined the key issues around diag-
nostics, assessment of severity, treatment and monitoring of
patients.
Conclusions In spite of advances in understanding the genetic
and molecular underpinnings of fibrous dysplasia/McCune-
Albright syndrome, clinical management remains a challenge.
From the workshop, a consensus was reached to create an
international, multi-stakeholder partnership to advance
The authors are grateful to all clinicians, researchers, and key patient
representatives of the FD/MAS partnership for their contributions to
this paper.
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research and clinical care in FD/MAS. We invite other stake-
holders to join the partnership.
Keywords Fibrous dysplasia . McCune-Albright syndrome .
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Introduction
Fibrous dysplasia (OMIM # 174800) is a rare disease affecting
the bone and is sometimes associated with endocrine dysfunc-
tion and skin pigmentation as part of McCune-Albright syn-
drome [1]. Fibrous dysplasia is due to a mosaic mutation dur-
ing embryogenesis leading to constitutive activation of the G-
protein alpha subunit in affected tissues including the bone,
endocrine glands, and skin [2]. Both children and adults report
poor physical function and pain, but preliminary data suggests
that they maintain emotional and social function [3, 4]. The
aims ofmanagement are to ensure patients realize their highest
quality of life. A number of recommendations for the diagno-
sis [5, 6] and management [6] of patients have been published.
Management focuses on confirming the diagnosis, determin-
ing the extent of disease, providing appropriate interventions,
and monitoring for complications. This requires involvement
of a multidisciplinary team across the lifetime of the affected
individual. The major challenge is to ensure all patients con-
sistently receive high quality care with minimal variation.
The aim of this initiative was to develop a global strategy
for future research and clinical guidance for improving patient
outcomes. To facilitate this, we engaged with the Fibrous
Dysplasia Support Society UK, and the Skeletal Rare
Disease Working Group of the International Osteoporosis
Foundation (SRD-IOF). The SRD-IOF is an international
working group which focuses on mentoring and knowledge
sharing, networking opportunities, developing bone-related
projects, and initiating advocacy activities and integration of
skeletal rare diseases of the bone into the general bone.
Method
In order to achieve the aim, a 3-day workshop was convened
in conjunction with UK patient support society, the Fibrous
Dysplasia Support Society (FDSS), the Oxford National
Institute for Health Research (NIHR) Musculoskeletal
Biomedical Research Unit, and the NIHR Musculoskeletal
Rare Diseases Translational Research Collaboration. The
workshop was structured into 3 days: patients with few clini-
cians on the patient workshop (day 1), both patients and
clinicians/researchers on the research workshop (day 2), and
only clinicians/researchers on the research workshop (day 3)
(agenda in supplementary materials).
Before the meeting, registered participants were sent a brief
questionnaire to elicit their research priorities across diagno-
sis, prognosis, and treatment as well as to suggest up to three
questions for research.
An update on the biology and clinical management for
adults and children with fibrous dysplasia/McCune-Albright
syndrome (FD/MAS) was presented, and patients and their
family members were invited to comment and discuss their
issues either within the wider group or in a one-to-one setting
with either Dr Collins or Dr Boyce.
For the research workshop, there were presentations of a
literature review of all publications in PubMED with the
MESH term BFibrous Dysplasia of Bone,^ clinical assessment
of bone pain, health-related quality of life, and costs in pa-
tients. The current and proposed activity of the International
Osteoporosis Foundation Skeletal Rare Disease Clinical
Scientific Advisors was presented followed by the research
activity and key research questions from National Institute
of Health (NIH), Leiden, Turin, Lyon, Florence, and Oxford.
The results from the participant survey were next presented.
This was followed by a discussion of the priorities for research
using expert opinion. The final clinical workshop was intro-
duced by state-of-the-art presentations on pediatric, adult, and
surgical management of patients with FD/MAS followed by
case presentations to stimulate discussion from the experts
present on developing a global clinical pathway.
Results
Patient workshop
Thirty-seven patients and 33 family members attended the
patient workshop with 3 doctors present. Following the pre-
sentations from doctors, the patients were able to reflect on the
day and ask questions. The theme of the comments by the
patients and family was focused on the lack of information
for both patients and clinicians and included:
BHow do I know what is the right and wrong informa-
tion on the web?^
BMy doctor did tell me I also had FD in the lower arm as
well as humerus and was told it did not hurt and not to
worry about it.^
BWho is going to look after her when she turns 17?^
BThe doctor looked at my x-ray of my head and got very
excited and said he had not seen this before. I felt a bit
like a prize cow and the doctor did not want to let me go
so had to fight to get referred to a Doctor who had seen
fibrous dysplasia before.^
Following the open session, a series of one-to-one consul-
tations between patients and MTC/AMB were undertaken.
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The feedback from these sessions was wholly positive.
Patients were encouraged to give details of their case histories
and examined when necessary. Some were then given sugges-
tions for further diagnostics and treatments.
Research workshop
Eight patients and 20 academics/clinicians were present.
Following short updates on the current evidence informing clin-
ical management of fibrous dysplasia, mechanisms of pain in the
bone, and value of economic assessments, the current and pro-
posed activity of the International Osteoporosis Foundation
Skeletal Rare Disease Clinical Scientific Advisors (website)
was presented. The current research activity and key research
questions from the representative institutions identified a number
of existing cohorts as well as two pilot studies of denosumab and
tociluzimab. The Lyon-developed diagnostic pathway [5] and
details about the National Institute of Health/National Center
for Advancing Translational Sciences (NIH/NCATS) Global
Rare Diseases Patient Registry Data Repository/GRDRSM were
also presented.
Ten patients/carers and nine clinicians/researchers
responded to the survey.While both ranked research into treat-
ment as the highest priority (55 and 65 %, respectively),
clinicians/researchers ranked prognosis (20 %) while patients
ranked diagnosis (35 %) as the next highest priority.
Several research priorities were identified (Table 1).
The highest priority research was improving our under-
standing of the natural history of FD. The method pro-
posed to achieve this was aggregation of cohort data al-
ready collected in tandem with the development of a pro-
spective cohort. The key outputs of the cohort would be to
(a) define the natural history, (b) determine additional
surrogate markers for clinical outcomes (to skeletal dis-
ease burden score [7] and phosphaturia [8]) and treatment
response, and (c) understand the mechanism of fibrous
dysplasia-related bone pain. From existing datasets, work
is needed to identify common questions as well as address
ethical and governance issues for pooling information be-
tween countries and working with the GRDR. Of note, the
patients’ present felt issues around data access were sur-
mountable and were willing to support any ethical issues.
One of the statements from the patients was their wish for
their information to be used for research. This was juxta-
posed with the researchers concerns not to contravene
national data protection regulations, and the group felt
this had to be carefully balanced lest we overlook the
right for the patients and their wishes to have their expe-
rience shared for the wider good.
An opportunity was identified to learn from existing inter-
national consortia that share data, such as the international
disorders of sex development [9] or the Brittle Bone
Disorders Consortium (https://www.rarediseasesnetwork.org/
cms/BBD). For the prospective cohort, key aspects would
include tools for pain assessment, fracture history, quality of
life (both generic and explored disease-specific tools), costs
(healthcare, informal, productivity losses, social care), stan-
dardized radiological imaging, biomarkers for disease activity,
and standardized tissue biosample-operating procedures. It
was recognized that if appropriately consented, the cohort
could also be offered participation in international clinical
trials. The group also expressed the need to establish novel
research and analytical methodology appropriate for rare
diseases.
From the post meeting feedback form, 100 % were willing
to attend the event again, and 14/15 thought the format could
Table 1 Research topic list
Domain Subject
Natural history/spectrum of disease International cohort to establish natural history and predictors of progression
Mechanisms of bone pain in FD including patient assessment of pain
Harmonize methods for diagnostics, demographics, biochemistry, bone sample processing, and storage
Measurement of quality of life using generic and development of disease-specific tools
Health, social care, and informal costs across the lifespan
Define the spectrum of extraskeletal manifestations in FD/MAS including neuropsychiatric,
gastro-intestinal, gynecological, and cardiac manifestations
Management RCT of current bone therapies to confirm efficacy
Novel therapies using small molecules
Improving the evidence base for orthopedic and craniofacial surgical indications and techniques
Management of extraskeletal manifestations including long-term gynecologic complications
in adults and pancreatic involvement
Prognosis Fertility and disease activity during pregnancy
Development of tools to aid in assessment of severity and assist in prognostication
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work for other diseases. In more detail, what can be improved:
more structured input from patients/have a patient representa-
tive speak at the research workshop; representation from or-
thopedics, craniofacial surgeons, radiologists, neurosurgeons,
dentists, specialist nurses, geneticists, basic researchers, and
radiologists; pre-meeting circulation of revised timetable; spe-
cific discussion on fertility; and provision of a microphone.
Other comments included BAs a patient it has been humbling
to see the level of knowledge, skill and passion being directed
into FD^ (from patient) and BHow will the international data-
base be used by pharma^ (from patient).
Clinical workshop
Fourteen clinicians/clinician scientists and one researcher
attended the clinical workshop. The rationale and content for
the NIH guidance were presented followed by a discussion on
key orthopedic issues. From the orthopedic presentation (FM),
the following concepts were discussed: operative and non-
operative interventions to improve function, role of prophy-
lactic stabilization, bone grafting, assessment of vascularity,
and choice of fixation. The subsequent discussion was split
into pediatric vs. adult and along four themes: diagnostics,
Table 2 Clinical topic list
Domain Subject Comment
Diagnostic Importance of isotope bone scintigraphy vs. whole body MR Sensitivity and practicality of whole body MR. When to delay
scintigraphy in children without overt bone disease
Role of biopsy and mutation analysis Heterogeneity of lesions affects sensitivity of biopsy-based
methods
Diagnostic pathways differs between Lyon and NIH Harmonization of diagnostic pathways with table of differential
diagnoses by site of lesion
Natural history of Mazabraud’s syndrome
Staging Staging evaluation to determine the extent of skeletal and
extraskeletal involvement should be performed in all
patients with suspected disease at initial presentation
Evidence-based guidelines to be determined by review of existing
literature and harmonization of the existing NIH and Lyon
pathways
Clinical assessment template differs between centers Harmonization of NIH clinical template to develop a global
clinical template tool. Identify key languages for translation
Which diagnostic tests to assess disease severity and
extraskeletal involvement
Long-term medical vs. surgical management of hyperthyroidism
Role of biochemical testing and pituitary MR in diagnosis
and management of growth hormone excess
Value of ongoing surveillance for progression of skeletal deformities
across the lifespan, including scoliosis, hearing and vision
deficits, and dental complications including mal-occlusions
Management The group acknowledged the importance of defining appropriate
indications for anti-resorptive therapy
The dose and timing of anti-resorptive therapy varied between sites.
The group consensus was to identify the maximum dosing for
induction therapy and then the rationale for the timing of main-
tenance therapy. Surveillance of possible side effects
of anti-resorptive therapy (osteonecrosis of the jaw, atypical
subtrochanteric femoral fractures, hypocalcaemia).
Methods for treatment of hypophosphatemia should be informed by
pathways in the management of other conditions of FGF23 excess
Use existing guidance for typical and atypical analgesics as
well as adjuvant interventions in those with chronic pain
Optimizing management of endocrinopathies, including
the impact on skeletal disease progression and pain
Effects of uncontrolled GH excess on craniofacial disease
progression. Effects of untreated or inadequately treated
hypophosphatemia on pain and fracture risk. Medical therapies
are effective for most endocrinopathies, and surgical
management for gonadal disease is not indicated.
Management of craniofacial FD Importance of routine vision and hearing monitoring. Prophylactic
optic nerve decompression in asymptomatic patients is
contraindicated.
The role of rehabilitation medicine and physiotherapy in
management of function, deformities, and pain
Guidance for dental health
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assessment of severity, treatment and monitoring, and the key
issues (Table 2).
From the post meeting feedback, 100 % were willing to
attend the event again and thought the format could work for
other diseases. In more detail, what worked well: clinical
cases, post lecture discussions/interaction; what could have
been improved: communications about timing, more cases;
other aspects that should have been covered included: indica-
tions for surgery in adult patients, specialist pain assessment
and management, include more orthopedic, craniofacial, neu-
rosurgeons and ENT surgeons.
Engagement and communication strategy
It was recognized that a number of centers and clinical spe-
cialties were not present, and a key next step is to ensure they
are invited to join the group. Other aspects of the engagement
strategy are shown in Table 3.
Discussion
The principal agreement of the meeting was the need for in-
ternational collaboration to improve the evidence base and
clinical care for patients with FD/MAS. Another key compo-
nent was the recognition that the current global variation in
patient care from diagnostics to assessment of severity, man-
agement, and monitoring was not evidence-based and may
also hinder improvement in the evidence base. Finally, the
value of a single template for evidence-based diagnostic and
treatment guidelines and research assessment was recognized
to enable audit of good practice as well as maximizing collab-
oration for research.
The format of the 3 days worked well by linking a patient
day, mixed patient/clinical/researcher day, and a pure clinical
day. The use of clinical cases to stimulate discussion on clin-
ical pathways was very successful. While there were specific
pediatric and adult sections to the day, most attendees
participated in both, allowing further sharing of experiences
in both directions and recognition of the importance of FD/
MAS management across the lifespan. There was a limited
surgical representation and no radiological representation.
Future meetings will need to address greater orthopedic, cra-
niofacial, and radiologist involvement as well as inviting other
centers to join the group. The workshop collated opinions
from the experts present, and a systematic review was not
performed given the low number of trials. We also recognize
that while a number of patients, family members, and carers
attended, theymay not be representative of the average patient
with FD.
In summary, we have described the successful initiation of
the international FD/MAS partnership that includes clinicians
and patients and the methods and outputs from the inaugural
meeting. We wish to extend the invitation for others to join
this partnership to support improving outcomes for patients
with FD/MAS. For more information please contact
rudy@ndorms.ox.ac.uk.
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